Early-stage structure-based drug discovery for small GTPases by NMR spectroscopy

Pharmacol Ther. 2022 Aug:236:108110. doi: 10.1016/j.pharmthera.2022.108110. Epub 2022 Jan 7.

Abstract

Small GTPase or Ras superfamily, including Ras, Rho, Rab, Ran and Arf, are fundamental in regulating a wide range of cellular processes such as growth, differentiation, migration and apoptosis. They share structural and functional similarities for binding guanine nucleotides and hydrolyzing GTP. Dysregulations of Ras proteins are involved in the pathophysiology of multiple human diseases, however there is still a stringent need for effective treatments targeting these proteins. For decades, small GTPases were recognized as 'undruggable' targets due to their complex regulatory mechanisms and lack of deep pockets for ligand binding. NMR has been critical in deciphering the structural and dynamic properties of the switch regions that are underpinning molecular switch functions of small GTPases, which pave the way for developing new effective inhibitors. The recent progress of drug or lead molecule development made for small GTPases profoundly delineated how modern NMR techniques reshape the field of drug discovery. In this review, we will summarize the progress of structural and dynamic studies of small GTPases, the NMR techniques developed for structure-based drug screening and their applications in early-stage drug discovery for small GTPases.

Keywords: Drug discovery; Molecular switches; NMR; Small GTPases; Structure and dynamics.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Drug Discovery
  • Humans
  • Magnetic Resonance Spectroscopy
  • Monomeric GTP-Binding Proteins* / metabolism
  • ras Proteins / metabolism

Substances

  • Monomeric GTP-Binding Proteins
  • ras Proteins